Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 69% Improvement Relative Risk c19ivm.org Efimenko et al. Ivermectin for COVID-19 LATE Is late treatment with ivermectin beneficial for COVID-19? PSM retrospective 41,608 patients in the USA (Jan 2020 - Jul 2021) Study compares with remdesivir, results vs. placebo may differ Lower mortality with ivermectin (p<0.000001) Self-censored, see notes Efimenko et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2021.12.096 Favors ivermectin Favors remdesivir

Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database

Efimenko et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.096
Efimenko et al., Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.096
Feb 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
PSM retrospective 41,608 patients in the USA, 1,072 treated with ivermectin and 40,536 treated with remdesivir, showing lower mortality with ivermectin treatment.
This study was presented at a conference (IMED 2021). Submissions were peer-reviewed. The treatment/control group sizes align with the estimated percentage of hospitals that used ivermectin vs. remdesivir. Hospitals in the USA receive financial incentives to use remdesivir.
Authors have self-censored the conference report of this result, not due to any error in the analysis, but because they believe ivermectin "has proven to be ineffective in clinical trials". This is incorrect, while some studies show no statistically significant effect, 59 studies show statistically significant positive results for one or more outcomes (33 prospective and 26 retrospective studies, including 23 RCTs) [Abbas, Ahmed, Ahsan, Alam, Aref, Aref (B), Babalola, Behera, Behera (B), Bernigaud, Biber, Borody, Budhiraja, Bukhari, Cadegiani, Carvallo, Carvallo (B), Chaccour, Chahla, Chahla (B), Chowdhury, de Jesús Ascencio-Montiel, de la Rocha, Desort-Henin, Efimenko, Elalfy, Espitia-Hernandez, Faisal, Ghauri, Gorial, Hashim, Hellwig, IVERCOR PREP, Kerr, Khan, Lim, Lima-Morales, Mahmud, Mayer, Merino, Mondal, Morgenstern, Mourya, Naggie, Okumuş, Ozer, Qadeer, Rajter, Rezai, Rezk, Samajdar, Seet, Shahbaznejad, Shimizu, Shouman, Soto-Becerra, Spoorthi, Tanioka, Thairu].
The self-censorship and decision not to submit to a journal provide further evidence of a negative publication bias for ivermectin research.
This is the 80th of 97 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion). 46 studies are RCTs, which show efficacy with p=0.00000014.
risk of death, 69.2% lower, OR 0.31, p < 0.001, treatment 1,072, control 40,536, propensity score matching, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Efimenko et al., 28 Feb 2022, retrospective, propensity score matching, USA, peer-reviewed, 6 authors, study period 1 January, 2020 - 11 July, 2021, dosage not specified, this trial compares with another treatment - results may be better when compared to placebo.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Development of Duplex and Multiplex Reverse Transcription Loop Mediated Isothermal Amplification (RT-LAMP) Assays for Clinical Diagnosis of SARS-COV-2 in Sri Lanka
M Hewadikaram, K Perera, K Dissanayake, M Ramanayake, S C Isurika, A Panch, A Jayarathne, P Pushpakumara, N Malavige, C Jeewandara, S D N K Bathige, A M Mubarak
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.095
Purpose: Despite the rollout of several vaccines targeting SARS-CoV-2, attainment of near-universal vaccination is a challenging task, particularly for low-and middle-income nations such as Sri Lanka. Rapid, reliable diagnostics for the detection of the virus is of vital importance for the predominantly export-and tourismbased economy of the country. Herein, we report the development of a RT-LAMP assay as an alternative to the gold-standard RT-qPCR method for diagnostic laboratories in Sri Lanka in a cost-effective and highly reliable manner. Methods & Materials: About 313 nasopharyngeal and oropharyngeal samples from the community were collected and subjected to RNA purification and subjected to simultaneous RT-qPCR and RT-LAMP experiments by using previously published primers in a thermocycler. Duplex (containing N and E gene primers) and multiplex (containing N, E and ORF1ab gene primers) RT-LAMP assay results were compared with standard RT-qPCR results using an agreement attribute statistical test. The effect of guanidine hydrochloride was also analyzed. Results: The limit of detection for the duplex assay was found to be 10 copies μL-1 at a constant temperature of 63 °C, and 5 copies μL-1 for multiplex assays at 66.4 °C. Both types of RT-LAMP assay were specific only for the SARS-COV-2 virus, successfully distinguishing it from multiple other human viruses. Attribute agreement analysis between duplex-and multiplex RT-LAMP vs RT-qPCR yielded 93% and 96.5% scores, respectively. Moreover, both RT-LAMP assays showed 100% agreement with RT-qPCR when Ct was < 25 in positive samples and showed 100% (duplex) or 97.22% (multiplex) at 35 ≥ Ct ≥25. The discrepancy between agreements at higher Ct values was attributed to the higher sensitivity of the multiplex RT-LAMP assay. The addition of guanidine hydrochloride increased the sensitivity and decreased detection time significantly for both the duplex and multiplex assays. Conclusion: Overall, we have demonstrated a potentially rapidly deployable diagnostic test kit not only for widespread community use but particularly for high-risk locations such as ports of entry or manufacturing facilities to mitigate the effects of the SARS-CoV-2 virus in Sri Lanka.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit